+1 8448850006
Product Launches

Svelte Medical Launches Slender Integrated Delivery System in the European Market

Company Report

 January 19, 2016, Svelte Medical Systems, US based coronary stent company, announced that he company has initiated a select launch of its Slender sirolimus-eluting coronary stent-on-a-wire integrated delivery system in European market. The device is equipped with Japan’s Asahi Intecc guide wire technology, specialized balloon design and DSM Biomedical’s bioresorbable drug carrier. The Slender’s all-in-one fixed wire system with all combined technologies provides doctors “precise steering” and controlled balloon growth for performing direct stenting even in state of high-pressure post-dilations, as stated by Svelte Medical.

On the occasion of launch of device in Europe, Jack Darby, CEO of Svelte Medical Systems quoted in a press release that “Slender IDS is a highly differentiated platform that fundamentally changes the way coronary stenting procedures are performed, and it will ultimately transform the DES landscape. We are excited to see physicians in the real-world share our enthusiasm for this novel platform.” 

Svelte Medical also announced its plans to begin enrollment for its next Direct III post-market study of the device in first quarter of 2016, with an aim to evaluate the “procedural efficiencies and 12-month clinical outcomes” of the device across population of Europe. On the announcement of the news, Dr. Giovanni Amoroso, principal investigator of study stated that “Downsizing is the future of interventional cardiology, and Slender IDS is the first ultra-low profile DES. The ability to reduce catheter size without compromise to performance minimizes vascular trauma and enables use of the transradial approach, with all of its well-known clinical benefits, across broader subsets of patients. This makes for a much more pleasant patient experience.” 

According to Pharmaion, pharma & healthcare consultants, the launch of the Slender sirolimus-eluting coronary stent-on-a-wire integrated delivery system in European market will help the company in strengthening its position in the European market. The launch would lead to paradigm shift in the interventional cardiology in Europe, generating good amount of revenue for Svelte Medical Systems.


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News